ALB

Albemarle Corp. 10-Q Summary: Period Ended September 30, 1996

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 1996, and the nine-month period ended on that date. Albemarle Corporation, a specialty chemicals company, underwent a significant strategic shift during this period. On March 1, 1996, the Company sold its alpha olefins, poly alpha olefins, and synthetic alcohol businesses ("Olefins Business") to Amoco Chemical Company for $487.3 million. Following this divestiture, Albemarle's operations focus on bromine chemicals, specialty chemicals, and detergents and surfactants. The Company also sold its electronic materials business in July 1995.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased significantly year-over-year due to the exclusion of the sold Olefins and electronic materials businesses. On an organic basis (excluding sold units), sales increased 3% for the nine-month period and 2% for the quarter.
• Profitability Surge: Net income for the nine months ended September 30, 1996, more than doubled to $138.15 million compared to $49.30 million in 1995. This increase was driven primarily by a one-time gain of $158.2 million from the sale of the Olefins Business.
• Debt Reduction: Total long-term debt plummeted from $200.1 million at year-end 1995 to $29.6 million at September 30, 1996, utilizing proceeds from the business sale.
• Share Repurchases: The Company repurchased approximately 11.2 million shares of common stock for $250.3 million during the nine-month period, including a tender offer of 9.5 million shares in April 1996.
• Operating Profit: Excluding the impact of divested businesses, operating profit was lower in 1996 due to higher costs in pharmaceutical intermediates (naproxen start-up) and lower operating rates in flame retardants and bromine fine chemicals.

Guidance, Outlook, and Risks

• Liquidity and Capital: Management anticipates that cash flow from operations will be sufficient to cover operating expenses, debt service, and dividends. Capital expenditures for the full year are expected to be significantly below 1995 levels, financed primarily by operating cash flow.
• Debt Covenants: A new $500 million credit facility was established in September 1996. It includes a covenant requiring consolidated indebtedness to remain below 60% of total capitalization. As of September 30, 1996, debt represented approximately 7.0% of total capitalization.
• Environmental and Legal: The Company is subject to environmental regulations and potential Superfund liabilities. An administrative proceeding regarding a potential penalty was settled in August 1996 for less than $100,000 plus a supplemental environmental project. Another OSHA proceeding involving a proposed $119,000 penalty is being contested.
• Unusual Items: The financial results are heavily influenced by the $158.2 million gain on the sale of the Olefins Business and the associated tax payments. Pro forma results excluding the sale show a net income of $42.9 million for the nine-month period.

Investor Verification Checklist

• Pro Forma Performance: Verify the pro forma earnings per share of $0.72 (nine months) to understand core operating performance excluding the one-time gain.
• Organic Growth: Confirm the 2-3% organic sales growth in remaining businesses (organometallics, bromine) against the backdrop of lower shipments in flame retardants.
• Cost Pressures: Review the impact of naproxen start-up costs and lower operating rates on future margins in pharmaceutical intermediates and flame retardants.
• Debt Structure: Confirm the terms of the new $500 million credit facility and the current utilization (zero outstanding as of filing date).
• Share Count: Note the significant reduction in outstanding shares (from ~66 million to ~55 million) and its impact on future EPS calculations.